Skip to content
DraconiticResearch
Search Sources API
194,220 studies31 sourcesUpdated 7 min ago
Peer-reviewedCC BY 4.0Frontiers in Endocrinology

Association of the remnant cholesterol inflammation index with long-term outcomes among patients with acute ischemic stroke treated with intravenous thrombolysis

  • Yuan Cheng1
  • Qingqing Wang2
  • Jinhua Liao3
  1. 1Fuyang Medical College, Fuyang Normal University
  2. 2Department of Neurology, The Affiliated Fuyang People’s Hospital of Anhui Medical University
  3. 3Department of Medical Oncology, Fuyang Cancer Hospital, Affiliated Fuyang Cancer Hospital of Fuyang Normal University
Open at sourceDOICite

Abstract

Background: The Remnant Cholesterol Inflammation Index (RCII) is a novel assessment tool that reflects lipid metabolism disorders and systemic inflammation, and may be associated with adverse vascular outcomes. This study aimed to investigate the relationship between RCII and long-term outcomes in patients with acute ischemic stroke (AIS) after intravenous thrombolysis (IVT).

Methods: We conducted a cohort study of 748 patients with AIS who received IVT between April 2019 and March 2025 and survived the index hospitalization. All patients were divided into four groups based on log-transformed RCII (lnRCII), and the endpoint events studied were recurrent ischemic stroke and all-cause mortality. Patients were followed from hospital discharge until March 31, 2026. We used survival and competing-risk analyses, Cox proportional hazards models, and restricted cubic splines to evaluate the associations between lnRCII and long-term outcomes.

Results: The median age was 68 years, the interquartile range was 59–76 years, 63.6% were male. During the follow-up period, recurrent ischemic stroke was confirmed in 101 (13.5%) patients, and all-cause mortality was confirmed in 120 (16.0%) patients. Multivariable Cox analysis showed that higher lnRCII levels were significantly associated with increased risks of recurrent ischemic stroke (HR = 1.373, 95% CI: 1.174-1.605, P < 0.001) and all-cause mortality (HR = 1.275, 95% CI: 1.107-1.469, P < 0.001). Restricted cubic spline analyses demonstrated no significant evidence of nonlinearity in the associations between lnRCII and either outcome (P for nonlinearity > 0.05). Sensitivity analyses yielded generally consistent findings. Exploratory subgroup analyses identified significant interactions with age and hypertension for all-cause mortality.

Conclusions: In patients with AIS treated with IVT, elevated RCII was independently associated with an increased risk of long-term recurrent ischemic stroke and all-cause mortality. RCII may prove to be a composite marker associated with long-term outcomes.

Related

  1. Machine learning-based models to predict 90-day non-excellent functional outcomes among patients with mild acute ischemic stroke after intravenous thrombolysis
    Yichen Wang, Xinyu Qiu, Yi Wang +1
    Frontiers in NeurologyPeer-reviewedCC BY 4.0Full textEpidemiology & public healthCrossrefEurope PMCPMCEurope PMC
  2. Association of endovascular treatment versus intravenous thrombolysis in mild stroke across occlusion subgroups
    Gao-Peng Xing, Xiao-Long Li, Ting-Ting Wang +1
    Frontiers in NeurologyPeer-reviewedCC BY 4.0Full textEpidemiology & public healthCrossrefEurope PMCPMC
  3. Real-world implementation and outcomes of extended-window intravenous thrombolysis in Catalonia, 2016-2024: A population-based study using the CICAT registry.
    C. del Valle-Vargas, M. Martinez-Sanchez, I. Vielba-Gomez +20
    medRxivPreprintPublic domainFull textNeurologymedRxiv
  4. Extending the Treatment Window for Intravenous Thrombolysis in Acute Ischemic Stroke
    Soheil Rahmati, Mohammadreza Alinejadfard, Yasaman Zarinfar +9
    Neurology: Clinical PracticePeer-reviewedLicence not statedFull text1 citedEpidemiology & public healthPMC
  5. Association between early intravenous magnesium sulfate administration and mortality according to systemic immune-inflammation index in critically ill patients with acute heart failure: A retrospective cohort study.
    Thanh Luan Nguyen, Hoang Ngoc Thao Duong, Thi Bao Yen Nguyen +4
    American heart journal plus : cardiology research and practicePeer-reviewedCC BY-NC-NDFull textEpidemiology & public healthEurope PMC

Cite

BibTeXRIS
BibTeX
@article{cheng2026association,
  title = {{Association of the remnant cholesterol inflammation index with long-term outcomes among patients with acute ischemic stroke treated with intravenous thrombolysis}},
  author = {Yuan Cheng and Qingqing Wang and Jinhua Liao},
  journal = {Frontiers in Endocrinology},
  year = {2026},
  month = nov,
  doi = {10.3389/fendo.2026.1984138},
  url = {https://www.frontiersin.org/articles/10.3389/fendo.2026.1984138/full},
  note = {CC BY 4.0},
}
RIS
TY  - JOUR
TI  - Association of the remnant cholesterol inflammation index with long-term outcomes among patients with acute ischemic stroke treated with intravenous thrombolysis
AU  - Yuan Cheng
AU  - Qingqing Wang
AU  - Jinhua Liao
PY  - 2026
DA  - 2026/11/05
JO  - Frontiers in Endocrinology
DO  - 10.3389/fendo.2026.1984138
UR  - https://www.frontiersin.org/articles/10.3389/fendo.2026.1984138/full
AB  - Background: The Remnant Cholesterol Inflammation Index (RCII) is a novel assessment tool that reflects lipid metabolism disorders and systemic inflammation, and may be associated with adverse vascular outcomes. This study aimed to investigate the relationship between RCII and long-term outcomes in patients with acute ischemic stroke (AIS) after intravenous thrombolysis (IVT).  Methods: We conducted a cohort study of 748 patients with AIS who received IVT between April 2019 and March 2025 and survived the index hospitalization. All patients were divided into four groups based on log-transformed RCII (lnRCII), and the endpoint events studied were recurrent ischemic stroke and all-cause mortality. Patients were followed from hospital discharge until March 31, 2026. We used survival and competing-risk analyses, Cox proportional hazards models, and restricted cubic splines to evaluate the associations between lnRCII and long-term outcomes.  Results: The median age was 68 years, the interquartile range was 59–76 years, 63.6% were male. During the follow-up period, recurrent ischemic stroke was confirmed in 101 (13.5%) patients, and all-cause mortality was confirmed in 120 (16.0%) patients. Multivariable Cox analysis showed that higher lnRCII levels were significantly associated with increased risks of recurrent ischemic stroke (HR = 1.373, 95% CI: 1.174-1.605, P < 0.001) and all-cause mortality (HR = 1.275, 95% CI: 1.107-1.469, P < 0.001). Restricted cubic spline analyses demonstrated no significant evidence of nonlinearity in the associations between lnRCII and either outcome (P for nonlinearity > 0.05). Sensitivity analyses yielded generally consistent findings. Exploratory subgroup analyses identified significant interactions with age and hypertension for all-cause mortality.  Conclusions: In patients with AIS treated with IVT, elevated RCII was independently associated with an increased risk of long-term recurrent ischemic stroke and all-cause mortality. RCII may prove to be a composite marker associated with long-term outcomes.
SN  - 1664-2392
ER  -